Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal

Zur Kurzanzeige

dc.identifier.uri http://dx.doi.org/10.15488/14995
dc.identifier.uri https://www.repo.uni-hannover.de/handle/123456789/15114
dc.contributor.author Toumi, Mondher
dc.contributor.author Dabbous, Omar
dc.contributor.author Aballéa, Samuel
dc.contributor.author Drummond, Michael F.
dc.contributor.author Schulenburg, Johann-Matthias Graf von der
dc.contributor.author Malone, Daniel C.
dc.contributor.author Neumann, Peter J.
dc.contributor.author Sullivan, Sean D.
dc.contributor.author Tunis, Sean
dc.date.accessioned 2023-10-18T06:09:11Z
dc.date.available 2023-10-18T06:09:11Z
dc.date.issued 2023
dc.identifier.citation Toumi, M.; Dabbous, O.; Aballéa, S.; Drummond, M.F.; von der Schulenburg, J.-M.G. et al.: Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal. In: Expert Review of Pharmacoeconomics and Outcomes Research (ERPO) 23 (2023), Nr. 5, S. 483-497. DOI: https://doi.org/10.1080/14737167.2023.2197214
dc.description.abstract Objective: No consensus exists on the ideal methodology to evaluate the economic impact and value of new, potentially curative gene therapies. We aimed to identify and describe published methodologic recommendations for the economic evaluation of gene therapies and assess whether these recommendations have been applied in published evaluations. Methods: This study was conducted in three stages: a systematic literature review of methodologic recommendations for economic evaluation of gene therapies; an assessment of the appropriateness of recommendations; and a review to assess the degree to which the recommendations were applied in published evaluations. Results: A total of 2,888 references were screened, 83 articles were reviewed to assess eligibility, and 20 papers were included. Fifty recommendations were identified, and 21 reached consensus thresholds. Most evaluations were based on naive treatment comparisons and did not apply consensus recommendations. Innovative payment mechanisms for gene therapies were rarely considered. The only widely applied recommendations related to modeling choices and methods. Conclusions: Methodological recommendations for economic evaluations of gene therapies are generally not being followed. Assessing the applicability and impact of the recommendations from this study may facilitate the implementation of consensus recommendations in future evaluations. eng
dc.language.iso eng
dc.publisher Abingdon : Taylor & Francis Group
dc.relation.ispartofseries Expert Review of Pharmacoeconomics and Outcomes Research (ERPO) 23 (2023), Nr. 5
dc.rights CC BY-NC-ND 4.0 Unported
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0
dc.subject Cost-effectiveness analysis eng
dc.subject economic evaluation eng
dc.subject gene therapy eng
dc.subject health technology assessments eng
dc.subject health-related quality of life eng
dc.subject onasemnogene abeparvovec eng
dc.subject spinal muscular atrophy eng
dc.subject systematic literature review eng
dc.subject.ddc 380 | Handel, Kommunikation, Verkehr
dc.subject.ddc 610 | Medizin, Gesundheit
dc.title Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal eng
dc.type Article
dc.type Text
dc.relation.essn 1744-8379
dc.relation.issn 1473-7167
dc.relation.doi https://doi.org/10.1080/14737167.2023.2197214
dc.bibliographicCitation.issue 5
dc.bibliographicCitation.volume 23
dc.bibliographicCitation.firstPage 483
dc.bibliographicCitation.lastPage 497
dc.description.version publishedVersion
tib.accessRights frei zug�nglich


Die Publikation erscheint in Sammlung(en):

Zur Kurzanzeige

 

Suche im Repositorium


Durchblättern

Mein Nutzer/innenkonto

Nutzungsstatistiken